Skip to main content

MedPath Trial Home

Organizations News Research

Data Sources:ClinicalTrials.govEU CTRFDAEMANMPATGAHealth CanadaWHO ICTRP

MedPath Trial Home

Search trials. Track pipelines. Understand approvals. With AI-powered intelligence for clinical research.

Product

Clinical Trials
Drug Intelligence
Global Approvals
AI Research
Pricing

Resources

FAQ
Search

Company

News
About
Contact

Legal

Privacy Policy
Terms of Service

Disclaimer: This website provides information retrieval and data analysis services. The content does not constitute medical advice. Eligibility assessments are for reference only and should not replace consultation with qualified healthcare professionals. Data is sourced from public registries and regulatory agencies; MedPath does not guarantee completeness or accuracy. Always verify information with primary sources.

© 2026 MedPath Trial. All rights reserved.

We value your privacy

We use cookies to analyze site traffic and improve your experience. See our Privacy Policy.

瑞易宁 - NMPA Drug Approval Details

Approvals/NMPA/Glipizide Extended Release Tablets

Approved

化学药品

Glipizide Extended Release Tablets

PFIZER INC.🇨🇳 National Medical Products Administration

Approval Date: Oct 14, 2024
Approval ID: 8iXrnCtJ5fe
Company: PFIZER INC.
Type: 化学药品

Approval Details

Approval Id: 8iXrnCtJ5fe
Approval Number: 国药准字HJ20160140
Generic Name: 格列吡嗪控释片
Generic Name En: Glipizide Extended Release Tablets
Trade Name: 瑞易宁
Drug Type: 化学药品
Dosage Form: 片剂
Strength: 5mg
Reg Date: 2024-10-14
Expired Date: 2029-10-13
Company Name: PFIZER INC.
Production Company Name: Viatris Pharmaceuticals LLC
Company Detail Path: /organization/pfizer-inc
Production Company Detail Path: /organization/viatris-pharmaceuticals-llc

Approved

Quick Info

Agency

NMPA

Country

🇨🇳

Approval Date

Oct 14, 2024

Approval ID

8iXrnCtJ5fe

Type

化学药品

Back to NMPA Approvals